{
    "organizations": [],
    "uuid": "75b838043b0021b03d345352643338979ca3d732",
    "author": "",
    "url": "https://www.reuters.com/article/brief-biogenand-abbvie-announcethe-volun/brief-biogenand-abbvie-announcethe-voluntaryworldwide-withdrawal-of-marketing-authorizations-forzinbryta-idUSFWN1QK0P1",
    "ord_in_thread": 0,
    "title": "BRIEF-Biogen And Abbvie Announce The Voluntary Worldwide Withdrawal Of Marketing Authorizations For Zinbryta",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 2, 2018 / 10:18 AM / in 10 minutes BRIEF-Biogen And Abbvie Announce The Voluntary Worldwide Withdrawal Of Marketing Authorizations For Zinbryta Reuters Staff 1 Min Read March 2 (Reuters) - Abbvie Inc: * BIOGEN AND ABBVIE ANNOUNCE THE VOLUNTARY WORLDWIDE WITHDRAWAL OF MARKETING AUTHORIZATIONS FOR ZINBRYTA® (DACLIZUMAB) FOR RELAPSING MULTIPLE SCLEROSIS * ABBVIE INC - EMA HAS INITIATED AN ARTICLE 20 REFERRAL PROCEDURE FOLLOWING REPORTS OF INFLAMMATORY ENCEPHALITIS AND MENINGOENCEPHALITIS * ABBVIE - ‍BIOGEN WILL CONTINUE TO WORK WITH REGULATORY AUTHORITIES & WITH HEALTHCARE PROVIDERS IN THEIR MANAGEMENT OF ZINBRYTA PATIENTS​ * ABBVIE - GIVEN NATURE OF ADVERSE EVENTS REPORTED, CHARACTERIZING PROFILE OF ZINBRYTA TO NOT BE POSSIBLE GOING AHEAD WITH LIMITED PATIENTS BEING TREATED * ABBVIE INC - BIOGEN BELIEVES VOLUNTARY WORLDWIDE WITHDRAWAL OF ZINBRYTA“IS IN BEST INTEREST OF PATIENTS” Source text for Eikon: Further company coverage:",
    "published": "2018-03-02T12:17:00.000+02:00",
    "crawled": "2018-03-02T12:41:46.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "minute",
        "abbvie",
        "announce",
        "voluntary",
        "worldwide",
        "withdrawal",
        "marketing",
        "authorization",
        "zinbryta",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "abbvie",
        "inc",
        "biogen",
        "abbvie",
        "announce",
        "voluntary",
        "worldwide",
        "withdrawal",
        "marketing",
        "authorization",
        "daclizumab",
        "relapsing",
        "multiple",
        "sclerosis",
        "abbvie",
        "inc",
        "ema",
        "initiated",
        "article",
        "referral",
        "procedure",
        "following",
        "report",
        "inflammatory",
        "encephalitis",
        "meningoencephalitis",
        "abbvie",
        "continue",
        "work",
        "regulatory",
        "authority",
        "healthcare",
        "provider",
        "management",
        "zinbryta",
        "abbvie",
        "given",
        "nature",
        "adverse",
        "event",
        "reported",
        "characterizing",
        "profile",
        "zinbryta",
        "possible",
        "going",
        "ahead",
        "limited",
        "patient",
        "treated",
        "abbvie",
        "inc",
        "biogen",
        "belief",
        "voluntary",
        "worldwide",
        "withdrawal",
        "zinbryta",
        "best",
        "interest",
        "patient",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}